tuneTypical Dose
200-600 mg/day cocoa flavanols
Supplement
Cocoa Extract
Cocoa Extract
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Start with 2-12 weeks for most practical outcomes.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Cocoa Extract is a medicinal plant or plant extract used in traditional systems. It is taken to target digestion, metabolic regulation, inflammation, or stress resilience.
Human evidence is often limited to small, heterogeneous trials. Reported benefits commonly include modest changes in dyspepsia symptoms, glycemic markers, lipids, or perceived stress. Minority findings include antimicrobial activity, immune modulation, and effects on liver enzymes, but these are frequently preclinical. Outcomes depend on standardization, dose, and baseline health.
Polyphenol-rich preparations may influence vascular/cognitive secondary endpoints in limited settings, not uniformly reproduced.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- adjunct symptom support
- tolerability improvement
Secondary Outcomes
- function score trend
- subjective wellbeing
Safety
Contraindications and Interactions
Contraindications
- Known cocoa/chocolate allergy
- Pregnancy or lactation without clinician guidance
- Unstable liver or kidney disease without clinician oversight
- Unresolved medication interaction risk (polypharmacy/high-risk regimens)
Side effects
- Gastrointestinal discomfort (usually mild)
- Headache or migraine in sensitive individuals
- Transient fatigue/sedation (ingredient-dependent)
- Possible acne flare with regular dark-chocolate intake
- Rare atopic dermatitis flare in sensitive individuals. Co-allergens may confound.
Interactions
No entries provided
Avoid if
- Unknown source quality or no heavy-metal testing
- Unstable medical conditions (especially active hepatic/renal injury)
- Complex medication stack with narrow therapeutic window medications
- Pregnancy/lactation without clinician guidance
Evidence
Study-level References
cocoa-extract-SRC-001Secondary evidence synthesis
Sourceopen_in_newSRC-002 synthesis anchored to PMID: 36102337, summarizing heterogeneous adult trial and review-level findings for cocoa extract outcomes.
Population: Adult human cohorts; mixed conditions and comparators
Dose protocol: Most studies use standardized cocoa-flavanol preparations in the low-to-moderate hundreds of mg/day
Key findings: Mixed to weak, often context-specific
Notes: Strong heterogeneity in dosing, endpoints, and outcome quality
Paper content
No consistent pooled superiority across all outcomes
cocoa-extract-SRC-002Secondary evidence synthesis
Sourceopen_in_newSRC-002 synthesis anchored to PMID: 36102337, summarizing heterogeneous adult trial and review-level findings for cocoa extract outcomes.
Population: Adult human cohorts; mixed conditions and comparators
Dose protocol: Variable
Key findings: No consistent pooled superiority across all outcomes
Notes: Inconsistent methods and selective reporting in available literature
Paper content
No consistent pooled superiority across all outcomes
cocoa-extract-SRC-003Randomized, double-blind, placebo-controlled trial (COSMOS substudy, 2x2 factorial).
Sourceopen_in_newHamaya R, Li S, Lau J, et al. Long-Term Effect of Cocoa Extract Supplementation on Incident Hypertension. Hypertension. 2025;82(10):1653-1662. doi:10.1161/HYPERTENSIONAHA.125.25209. PMID:40832703.
Population: Older US adults without baseline hypertension from the COSMOS trial.
Dose protocol: 500 mg cocoa flavanols per day (80 mg epicatechin) versus placebo for median 3.4 years in 8,905 older adults.
Key findings: No overall reduction in incident hypertension (HR 0.96). In participants with baseline SBP below 120 mmHg, 24% hypertension risk reduction (HR 0.76).
Notes: Large COSMOS substudy. Null overall result, but meaningful subgroup signal for normotensive individuals. Industry co-funded.
Paper content
This large COSMOS substudy tested whether long-term daily cocoa extract supplementation (500 mg flavanols) could prevent incident hypertension in 8,905 older adults without baseline hypertension. Over a median follow-up of 3.4 years, cocoa extract did not significantly reduce overall hypertension incidence. However, in a pre-specified subgroup of participants with baseline systolic BP below 120 mmHg, supplementation reduced hypertension incidence by 24%, with effects emerging after year 2. This is one of the largest and longest trials of cocoa flavanols for a hard cardiovascular endpoint, adding important nuance to the blood pressure story. The overall null result tempers enthusiasm, while the subgroup finding suggests potential benefit in normotensive individuals over extended use.
cocoa-extract-SRC-004Randomized, double-blind, placebo-controlled trial (COSMOS substudy, 2x2 factorial).
Sourceopen_in_newLi S, Hamaya R, Zhu H, et al. Effects of 2-year cocoa extract supplementation on inflammaging biomarkers in older US adults: findings from the COSMOS randomised clinical trial. Age Ageing. 2025;54(9):afaf269. doi:10.1093/ageing/afaf269. PMID:40966617.
Population: Older US adults from the COSMOS trial with biospecimens at baseline and years 1 and 2.
Dose protocol: 500 mg cocoa flavanols per day versus placebo for 2 years in 598 older adults.
Key findings: hs-CRP decreased 8.4% versus placebo (P=0.008). IFN-gamma increased 6.8% (P=0.011). IL-6, IL-10, TNF-alpha did not differ.
Notes: Provides mechanistic inflammatory biomarker support for the cardiovascular protection signal from the main COSMOS trial.
Paper content
This COSMOS substudy examined the effects of 2-year cocoa extract supplementation on inflammaging biomarkers in 598 older adults. The cocoa extract group showed a significant 8.4% yearly decrease in hs-CRP compared to placebo (P=0.008) and a 6.8% increase in interferon-gamma (P=0.011). The broader COSMOS trial had previously reported a 27% reduction in cardiovascular disease death. These biomarker findings provide a mechanistic window into how cocoa flavanols may reduce cardiovascular risk through anti-inflammatory pathways. The study adds valuable long-term inflammatory biomarker data to the COSMOS evidence base, though the subsample size is modest relative to the full trial.